{"id":"W2476422824","doi":"10.1158/1538-7445.am2016-ct097","title":"Abstract CT097: A first-in-human phase I dose escalation study of the OX40 agonist MOXR0916 in patients with refractory solid tumors","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Immunotherapy; Internal medicine; Oncology; Agonist; Cohort; Adverse effect; Refractory (planetary science); Cancer; Gastroenterology; Urology; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001237244,0.0016152,0.001778177,0.0004656365,0.0004466173,0.0009718389,0.0008339992,0.000959516,0.003812878],"category_scores_gemma":[0.0007710834,0.0005016212,0.0008591973,0.0004687877,0.0009377662,0.0007470085,0.000409051,0.003108868,0.001177341],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009639082,"about_ca_system_score_gemma":0.001732451,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001252606,"about_ca_topic_score_gemma":0.002632572,"domain_scores_codex":[0.9996096,0.0001920459,0.00002177321,0.00006103437,0.00003531243,0.00008018893],"domain_scores_gemma":[0.999426,0.0000869264,0.00009160949,0.00005853068,0.00004879092,0.0002881418],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5205418,0.1036885,0.01328754,0.001401947,0.001693916,0.0006118682,0.0007895601,0.006639857,0.1880036,0.0006062124,0.01032458,0.1524106],"study_design_scores_gemma":[0.3371467,0.6312135,0.01518493,0.00005234121,0.0004435272,0.0005343779,0.00008339998,0.001823213,0.009354712,0.000196003,0.003923665,0.00004357506],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.992362,0.001258953,0.0006934931,0.0003797955,0.00007010227,0.002242099,0.0012346,0.0001581193,0.001600709],"genre_scores_gemma":[0.988328,0.001131249,0.002149027,0.0006296136,0.0001097551,0.002054576,0.002849005,0.00005978127,0.002688885],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003812878,"threshold_uncertainty_score":0.01275533,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05143809461649836,"score_gpt":0.406335398078654,"score_spread":0.3548973034621557,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}